Can Dexmedetomidine Prevent the Unwanted Hemolytic Events in the Glucose-6-Phosphate Dehydrogenase-deficient Person Undergoing Cardiac Surgery?
Manijeh Yousefi Moghadam
Department of Anesthesiology and Intensive Care, Cardiac Anesthesia Fellowship, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
|Date of Web Publication||19-Dec-2018|
Dr. Manijeh Yousefi Moghadam
Department of Anesthesiology and Intensive Care, Cardiac Anesthesia Fellowship, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Yousefi Moghadam M. Can Dexmedetomidine Prevent the Unwanted Hemolytic Events in the Glucose-6-Phosphate Dehydrogenase-deficient Person Undergoing Cardiac Surgery?. Adv Biomed Res 2018;7:155
|How to cite this URL:|
Yousefi Moghadam M. Can Dexmedetomidine Prevent the Unwanted Hemolytic Events in the Glucose-6-Phosphate Dehydrogenase-deficient Person Undergoing Cardiac Surgery?. Adv Biomed Res [serial online] 2018 [cited 2020 Jan 28];7:155. Available from: http://www.advbiores.net/text.asp?2018/7/1/155/247973
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most frequent human enzyme deficiency, affecting at least 400 million people globally. The G6PD enzyme plays an essential role in the production of nicotinamide adenine dinucleotide phosphate (NADPH), which is an intracellular antioxidant enzyme. The production of NADPH is impaired in patients who suffer from G6PD enzyme deficiency. This can predispose erythrocytes to oxidative metabolites stress and ultimately causing hemolysis. For clinicians, the most important point to consider about G6PD deficiency is the asymptomatic nature of this abnormality, such that G6PD-deficient patients develop clinical manifestations of hemolysis only under specific situations such as infection, food (fava beans), certain drugs, diabetic ketoacidosis, neonatal age, and stressors with oxidative actions. In the list of anesthetic drugs that should be avoided are propofol, benzodiazepines, ketamine, and fentanyl. Therefore, one of the most important considerations that anesthesiologists have to contemplate in the management of G6PD deficiency patients is avoiding these stressors and triggering factors in addition to reducing the pain and stress of surgery by selecting the suitable anesthetic and analgesic medications.
Cardiac surgery is associated with a considerable increase in systemic oxidative stress and free radicals. The erythrocytes of a G6PD-deficient patient undergoing cardiac surgery are incapable of scavenging these free radicals, resulting in hemolysis; hence, G6PD deficiency can trigger the destructive effect of free radicals in such patients. Due to the production and accumulation of toxic peroxides, injection of some anesthetic and analgesic agents before, during, and after cardiac surgery can initiate the oxidation of red blood cell membrane and hemoglobin in patients with G6PD deficiency, and thus, these drugs might have the potential to evoke acute episode of hemolysis. As a result, the induction of anesthesia with oxidative agents in G6PD deficiency patients undergoing cardiac surgery multiplies the risk of hemolysis. Nevertheless, the evidence regarding the effects of currently used anesthetic and analgesic agents on G6PD enzymatic activity in patients undergoing cardiac surgery is lacking, and selecting the best anesthetic and analgesic agent in these patients is controversial., Consequently, this inconsistency and uncertainty concerning conflicting data may limit the use of analgesics for sedation and pain control in patients with G6PD deficiency.
Recently, some sedative agents with analgesic and anesthetic properties such as dexmedetomidine (DEX) have shown promising effects in minimizing the potential for oxidative stress and hemolysis during before, during, and after surgery in G6PD-deficient infants. DEX, a selective alpha2-adrenoceptor agonist, is a sedative agent with concurrent anesthetic, anti-anxiety, antioxidant, and opioid-sparing effects. It has been reported that DEX can significantly decrease the levels of inflammatory cytokines and free radicals during cardiac surgery. In addition, it has minimal effects on the respiratory and cardiovascular functions after surgery, which facilitates rapid recovery of patients. To prevent the unwanted events of hemolysis in the G6PD-deficient person undergoing cardiac surgery, it seems that DEX has potential to be a good candidate for sedation, induction, and maintenance of anesthesia, as well as for analgesia after surgery. However, owing to the dearth of evidence, it is not possible to make strong evidence-based recommendations on the use of DEX in G6PD-deficient person. As a result, future research should be aimed at providing answers to this question: Can perioperative DEX prevent the unwanted hemolytic events in the G6PD-deficient person undergoing cardiac surgery?
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Luzzatto L, Arese P. Favism and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 2018;378:60-71.
Pan W, Wang Y, Lin L, Zhou G, Hua X, Mo L. Outcomes of dexmedetomidine treatment in pediatric patients undergoing congenital heart disease surgery: A meta-analysis. Paediatr Anaesth 2016;26:239-48.
Takahashi N, Ogawa T, Wajima Z, Omi A. Dexmedetomidine-based intravenous anesthesia of a pediatric patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency: A case report. Medicine (Baltimore) 2017;96:e6986.
Chowdhry V, Bisoyi S, Mishra B. Perioperative challenges in a patient of severe G6PD deficiency undergoing open heart surgery. Ann Card Anaesth 2012;15:50-3.
] [Full text]
Valiaveedan S, Mahajan C, Rath GP, Bindra A, Marda MK. Anaesthetic management in patients with glucose-6-phosphate dehydrogenase deficiency undergoing neurosurgical procedures. Indian J Anaesth 2011;55:68-70.
] [Full text]
Gerrah R, Shargal Y, Elami A. Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients with glucose-6-phosphate dehydrogenase deficiency. Ann Thorac Surg 2003;76:523-7.
Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, et al.
Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review. Drug Saf 2010;33:713-26.
Ueki M, Kawasaki T, Habe K, Hamada K, Kawasaki C, Sata T. The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. Anaesthesia 2014;69:693-700.